Recently,Boston Scientific (NYSE: BSX) announced that it has signed a definitive agreement to acquire Cortex, Inc., a subsidiary of Ajax Health LLC, and its FDA-approved OptiMap system.In order toComplement Boston Scientific's Electrophysiology Product Portfolio, providing solutions to advance the treatment of complex atrial fibrillation.

According to customary closing conditions, Boston Scientific expects to complete the transaction in the first half of 2025. Although the financial terms have not been disclosed, it is not difficult to see from the business of the acquisition target.This transaction is of great significance to Boston Scientific.

AsPioneer in the Field of Electrophysiology, despite Boston Scientific having made certain progress, it still faces challenges fromJohnson & Johnson, Abbott, and MedtronicIntense competition from rivals.

Especially Johnson & Johnson, itsThe Carto 3 system is the three-dimensional mapping system with the highest market share.. As one of the traditional three major players in electrophysiology, Boston Scientific, despite having its own 3D mapping system OPAL HDx, still lags behind Carto 3. Therefore, it also needsM&A to Strengthen, and Cortex's mapping system OptiMap is undoubtedly the best choice.

As a company focused on developing comprehensive mapping and ablation solutions for the treatment of atrial fibrillation (AFib),Cortex's Core Product OptiMap™ System, the innovative use of basket catheters and proprietary algorithms can identify triggers and drivers outside the pulmonary veins, helping doctors provide precise personalized ablation strategies to improve surgical efficiency and treatment outcomes.

This system received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2023 and has recently completed the FLOW-AF randomized controlled clinical trial, with its safety and efficacy clinically recognized and validated.

By acquiring Cortex, especially obtaining the OptiMap system, willHelp Boston Scientific compete more fiercely with Johnson & Johnson in the 3D mapping field.

According to the Global President of Boston Scientific's Electrophysiology Business:

"The addition of Cortex technology complements our electrophysiology portfolio, providing a differentiated cardiac mapping product for complex atrial fibrillation cases."The OptiMap system has proven to help doctors design targeted ablation strategies for complex cases, thereby improving the surgical efficiency and outcomes for patients with challenging atrial arrhythmias. We look forward to advancing this technology and promoting the generation of future clinical evidence, with the goal of making this technology accessible to doctors and patients worldwide in the coming years.

In fact, this is not the first time that Boston Scientific has increased its investment in cardiac electrophysiology business in recent years.

As early as 2021, Boston Scientific completed a highly complementary integration with its own electrophysiology product line.The Acquisition of FarapulseAt that time, Farapulse's PFA product received approval for market launch in January of the same year, becomingThe World's FirstPFA products on the market.

Subsequently, Boston Scientific rapidly expanded its presence in the cutting-edge electrophysiology market. Through aggressive acquisitions and the approval of multiple new products, it embarked on an all-out offensive strategy marked by bold moves:

This renewed investment in Cortex, with its differentiated cardiac mapping technology, complements Boston Scientific's electrophysiology portfolio capabilities. With this, Boston Scientific has achieved a comprehensive layout and strengthened core technologies in the two key tracks of electrophysiology—3D mapping and ablation—building its own competitive moat.

So, why does Boston Scientific, as a comprehensive medical device giant, continue to expand its electrophysiology business territory?

Boston Scientific's frequent enhancement of this technology is not just a case of "having money and being任性", but rather the result of repeatedly acquiring cutting-edge technology.Positive RevenueOnly then did the company have the confidence to keep increasing its investment. This acquisition of Cortex is no exception.

According to the Q3 2024 financial report released by Boston Scientific, it shows thatRevenue from the electrophysiology (EP) business increased by 177% year-over-year.The report stated that in the third quarter, the company's profit reached 468 million US dollars, with earnings per share of 32 cents, and total sales amounted to 4.21 billion US dollars.

Moreover, according to a survey of 25 U.S. electrophysiologists conducted in the first half of this year, within the next 12 months,The use of PFA will increase from 9% today to over 30%.Most doctors said that PFA would enable them to perform more cardiac surgeries.

It can be foreseen that in the future, Boston Scientific, which owns the OptiMap mapping system, will also usher in a new explosion. This acquisition, for Boston Scientific, is equivalent to creating another performance engine.

Currently, Boston Scientific's market share in the electrophysiology ablation field is only 6%, but it is projected to rise above 16% in the next 12 months, with its sales in the United States expected to increase by $440 million.

Returning to the technology itself, pulsed field ablation (PFA) has advantages over traditional radiofrequency ablation or cryoablation, such as tissue specificity, non-thermal ablation, long-lasting effects, and safety, and is gradually replacing traditional thermal ablation methods.

Although this market is still in the early stage of development, in today's"Involution"Clear electrophysiology track,Johnson & Johnson, MedtronicLeading medical device companies have long regarded pulsed field ablation as a new strategic high ground.

Although PFA has made breakthroughs in enhancing safety, challenges remain during the ablation process, particularly regarding the recurrence of atrial fibrillation. A key factor in AF recurrence is the difficulty in accurately assessing during surgery whether abnormal electrophysiological tissues have been completely ablated. To fully eliminate these abnormal tissues, three-dimensional mapping technology must be utilized for precise identification. Thus,3D mapping has also become the key for various companies to achieve breakthroughs in PFA products.

In this field, Johnson & Johnson's three-dimensional mapping technology has always been in a leading position. In recent years, although Boston Scientific has been constantly catching up, there is still a gap with Johnson & Johnson in the mapping technology that plays a key role in pulse ablation. Therefore, at this stage, Boston Scientific’s adoption of a mergers and acquisitions strategy to strengthen its own three-dimensional mapping system is an inevitable choice in market competition.

As the third largest track in the field of cardiovascular interventional treatment devices, cardiac electrophysiology has enormous market potential.

It is estimated that the global electrophysiology market size was USD 79.8 billion in 2023 and is expected to reach$15.09 billion, with a compound annual growth rate (CAGR) of 8.30% from 2024 to 2031.

Driven by such a huge market potential, the giants never stop their fierce battles of innovation and technology. Since the beginning of this year,Johnson & Johnson, Medtronic, AbbottOthers are also actively promoting the research and development and approval of PFA core technology for existing PFA products.Further Explore the Space for Technological Upgrades, in order to improve the PFA product, all parties are striving to gain more competitive advantages for the subsequent market competition.

As a giant in electrophysiology, Johnson & Johnson's Thermocool SmartTouch SF + Carto 3 has long been a benchmark in the field of radiofrequency ablation for atrial fibrillation, especiallyCarto 3 is Johnson & Johnson's most advanced three-dimensional mapping system., occupying an absolutely dominant position among the eight 3D mapping systems launched globally.

In 2022, Johnson & Johnson once again made a massive investment of $16.6 billion to acquire cardiac device manufacturer Abiomed, supplementing its Biosense Webster electrophysiology business and further expanding Johnson & Johnson's presence in the cardiovascular sector.

On this basis, Johnson & Johnson officially launched at the beginning of this monthFirst PFA Ablation Catheter --- VARIPULSE Receives FDA Approval for Market Launch, This is also the first and only PFA technology integrated with Carto 3, achieving an intuitive and reproducible workflow through real-time visualization and feedback mechanisms. Carto is Johnson & Johnson's greatest advantage in the PFA field to outperform other competitors in the future.

GoIn the year, Medtronic acquired Affera for $925 million, taking overSphere-9 Dual-Energy Ablation Catheter and Affera 3D Mapping System, which not only fills the gap in the PFA pulse ablation field but also enhances its three-dimensional mapping system.

In December of the same year, Medtronic's PulseSelect Pulsed Field Ablation (PFA) System was successfully approved by the FDA, becomingChinaThe World's First FDA-Approved PFA Pulse Ablation Product, which successfully preempted Boston Scientific, the leader in the pulsed field ablation domain.

Last month, Medtronic announced that the FDA had approved its Affera™ Mapping and Ablation System with the Sphere-9™ catheter, an integrated, high-density mapping, pulsed field, and radiofrequency ablation catheter. This marks another PFA product from Medtronic to gain FDA approval following PulseSelect, giving the company more leverage with two PFA technologies at its disposal.

Abbott has two three-dimensional electrophysiology mapping and navigation systems. They areEnSite Precision Mapping System and EnSite™ X EP Mapping System, which was also iteratively upgraded and launched after the acquisition of St. Jude in 2017.

At the same time, Abbott also recently disclosed that its Volt™ PFA systemGlobal IDE Registration Completed Ahead of Schedule; The tacticalflex™Duo ablation catheter SensorEnabled™ is undergoing the global FOCALFLEX trial; The Advisor™HDGridX mapping catheter SensorEnabled™ has received approval from the U.S. Food and Drug Administration and commercial launch has begun.

The rapid expansion of the PFA market has not only intensified competition among overseas giants but also driven the breakthrough of domestically produced alternatives. In the Chinese market, there is also a steady stream of good news:

Recently,Maiv Micro MedicalThe cardiac pulse electric field ablation catheter and the disposable cardiac pulse electric field ablation catheter from Minimally Invasive Electrophysiology,Enter the special review process for innovative medical devices.

Last year,Jinjiang ElectronicsLEAD-PFA Cardiac Pulsed Field Ablation System and PulsedFA Single-Use Cardiac Pulsed Field Ablation CatheterReceived NMPA Marketing Approval, achieving a breakthrough to become the first PFA product approved for marketing in China.

Besides, in ChinaHuitai Medical, Micro EP, Denuo EP, Yuanshan Medical, Aikema EP, Zhouling Medical, Hanyu Medical, Maiwei Medical, Beixing Medical, Xuanyu Medical, Shangyang Medical, Ruidi BiotechA batch of enterprises have invested in the PFA track, with many products entering the clinical trial or registration approval stage.

As the world's second-largest medical device market, China will also become one of the most competitive markets globally. According to data statistics, the domestic market size will reach 6.2 billion yuan in 2020. It is expected that by 2024, the number of electrophysiological surgeries will reach 373,000 cases, with a compound annual growth rate of 15.7%.

Although the development of electrophysiology in China started relatively late, with the advancement of technology, domestic brands are now beginning to step onto the stage in the competition for the PFA market. International giants such as Boston Scientific, Johnson & Johnson, and Medtronic are making comprehensive efforts, while Chinese manufacturers are also accelerating their progress, unwilling to fall behind.

Currently inCost Control in China's Medical Insurance and Support for Innovative Medical Devices Made in ChinaAgainst the broader backdrop, the substitution of domestically produced electrophysiology devices will continue to advance. Under the implementation of DRG/DIP policies, doctors in China will have more incentive to try domestic products as alternatives to imported ones.

Although in the PFA field, giants such as Boston Scientific and Johnson & Johnson have continuously strengthened their core technologies through acquisitions, the intensifying competition within the global electrophysiology market will still lead to numerous...Chinese enterprises with strong capabilities are surrounded by competitors.Whether these giant companies can constantly intensify their efforts to disrupt the market pattern and achieve dual breakthroughs in technology and performance in the electrophysiology field still needs time to answer.